(BBIO) BridgeBio Pharma - Performance 69.8% in 12m
BBIO performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
19.74%
#17 in Peer-Group
Rel. Strength
89.95%
#747 in Stock-Universe
Total Return 12m
69.76%
#18 in Peer-Group
Total Return 5y
44.19%
#22 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 45.12 USD |
| 52 Week Low | 22.35 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 82.83 |
| Buy/Sell Signal +-5 | 0.12 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: BBIO (69.8%) vs XBI (-10.7%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.32% | 68% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-10.6% | -8.81% | 144% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
0.71% | -3.57% | 32.5% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
-0.36% | 31.7% | -6.18% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
2.76% | -8.64% | 0.27% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.5% | 65.3% | -5.65% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
-0.49% | 55.9% | -10.1% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
3.44% | 35.3% | 14.7% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: BBIO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for BBIO
| Total Return (including Dividends) | BBIO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 20.64% | 2.27% | 4.52% |
| 3 Months | 29.56% | 6.30% | 10.43% |
| 12 Months | 69.76% | -10.68% | 14.67% |
| 5 Years | 44.19% | -26.13% | 109.23% |
| Trend Score (consistency of price movement) | BBIO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 93.8% | 5.5% | 79.1% |
| 3 Months | 67.8% | 74.3% | 94.2% |
| 12 Months | 81.6% | -84.7% | 44.4% |
| 5 Years | -25.5% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th86.00 | 17.96% | 15.43% |
| 3 Month | %th76.00 | 21.88% | 17.32% |
| 12 Month | %th92.00 | 90.05% | 48.04% |
| 5 Years | %th90.00 | 95.19% | -31.09% |
FAQs
Does BridgeBio Pharma (BBIO) outperform the market?
Yes,
over the last 12 months BBIO made 69.76%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.68%.
Over the last 3 months BBIO made 29.56%, while XBI made 6.30%.
Performance Comparison BBIO vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
BBIO vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -5.6% | 16.1% | 45.4% | 55% |
| US NASDAQ 100 | QQQ | -5.1% | 16% | 44.2% | 56% |
| German DAX 40 | DAX | -3.9% | 21.7% | 34% | 41% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -4.6% | 16.5% | 44.5% | 52% |
| Hongkong Hang Seng | HSI | -3.8% | 14.6% | 27.7% | 34% |
| India NIFTY 50 | INDA | -5.7% | 18.3% | 47.1% | 70% |
| Brasil Bovespa | EWZ | -6.7% | 13.1% | 22.6% | 57% |
BBIO vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -6.2% | 14.6% | 40.3% | 42% |
| Consumer Discretionary | XLY | -5% | 18.6% | 52.6% | 49% |
| Consumer Staples | XLP | -4.6% | 21.1% | 45.8% | 59% |
| Energy | XLE | -4.4% | 16.3% | 51.5% | 73% |
| Financial | XLF | -5.9% | 17% | 41.7% | 40% |
| Health Care | XLV | -6% | 17.1% | 51.5% | 74% |
| Industrial | XLI | -5.8% | 16.6% | 38.3% | 45% |
| Materials | XLB | -6.5% | 16.4% | 42.4% | 64% |
| Real Estate | XLRE | -2.4% | 20% | 46.6% | 56% |
| Technology | XLK | -5.3% | 12.7% | 43.1% | 59% |
| Utilities | XLU | -4.2% | 20.2% | 42.8% | 45% |
| Aerospace & Defense | XAR | -6.2% | 13.4% | 27% | 21% |
| Biotech | XBI | -2.9% | 18.4% | 60.9% | 80% |
| Homebuilder | XHB | -8.1% | 10.2% | 52% | 65% |
| Retail | XRT | -6.6% | 16.2% | 51.1% | 60% |
BBIO vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -5% | 14.3% | 55.6% | 79% |
| Natural Gas | UNG | 3.3% | 31.1% | 62.9% | 79% |
| Gold | GLD | -4.2% | 22% | 26.4% | 27% |
| Silver | SLV | -4.1% | 17% | 30.2% | 48% |
| Copper | CPER | -6.6% | 16.7% | 27% | 55% |
BBIO vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -4.6% | 17.1% | 49.3% | 68% |
| iShares High Yield Corp. Bond | HYG | -3.8% | 19.4% | 47.6% | 60% |